Title: Chief Executive Officer, Chair
Location: Boston, Massachusetts, United States
David R. Elmaleh, PhD, Chief Executive Officer and Chair at AZTherapies, has been recognized by Marquis Who’s Who Top Doctors for dedication, achievements, and leadership in pharmaceuticals.
Dr. Elmaleh is a renowned molecular imaging expert and inventor of numerous molecular imaging agents, including three drugs that are in use or in late stage clinical trials, including radiopharmaceutical preparation of (2FDG), which has been used in millions of PET imaging procedures. He also has patent protection for the use of 18F-FDG PET for imaging atherosclerosis, which tracks inflammation within plaques and for monitoring the response to drug therapy. On top of these achievements, Dr. Elmaleh is the inventor of more than 50 issued and pending patents. In his current endeavors, Dr. Elmaleh is working towards the development of a combination therapy for Alzheimer’s that is in a phase three trial. He hopes to continue this line of work by focusing on unmet needs in the area of neurodegeneration and the aging process.
Dr. Elmaleh embarked on his professional journey by first earning a Bachelor of Science in chemistry and physics from The Hebrew University. He continued his education at the institution to receive a Master of Science in physical organic chemistry and a PhD. Dr. Elmaleh credits his success to working at great institutions such as Harvard and receiving a well-rounded education, and he believes his peers and colleagues have played a role in his career. Dr. Elmaleh believes innovation comes from trying to solve problems where others have failed and addressing those causes of failure. Additionally, Dr. Elmaleh believes that because he came from another field before medicine gave him a fresh perspective that is useful in the drug development process.
In 2016, Dr. Elmaleh helped launch Pure Tech Health. He has also founded Molecular Insight Pharmaceuticals, Inc. and Mersana Therapeutics. He has maintained professional affiliation with the Society of Nuclear Medicine, the American Chemical Society and the American Association for the Advancement of Science. In addition, he has taught as an associate professor at Harvard University and worked as the Director of Contrast Media Chemistry at Massachusetts General Hospital. Throughout his career, his work has been nominated as one of the 25 Most Valuable Inventions of the Brain of the Decade. Looking toward the future, Dr. Elmaleh hopes that the field of neurodegeneration continues to advance and make a difference in people’s lives.
Contact Dr. Elmaleh